Amy Guan

CSO

Puhe Biopharma

Short Biography

Amy Guan, Ph.D., is the CSO of Puhe Biopharma, a biotechnology company advancing therapies in oncology, immunology, and metabolic diseases through small molecules, targeted protein degraders, and AI-driven discovery.

She previously served as CTO at UProtech Therapeutics, leading targeted protein degradation programs. Dr. Guan has over 15 years of drug discovery leadership experience at Chinese companies, including Yangtze River Pharmaceuticals and WuXi AppTec, and earlier spent 12 years in medicinal chemistry leader roles at AstraZeneca and Pfizer in the United States.  She has advanced 10 drug candidates into clinical trials.

She received her Ph.D. from the Shanghai Institute of Organic Chemistry and completed postdoctoral research at the Michigan Cancer Foundation.

Presentation Topic: Development and Exploration of Next-Generation Targeted Protein Degraders

• Development of next-generation PROTAC degraders for inflammatory diseases 

• Targeting previously “undruggable” proteins through induced protein degradation

• AI-assisted computational modeling to optimize PROTAC design and ternary complex cooperativity